SRSAU $10.04 0%
ROSE $10.52 -0.473%
7552.HK $7.20 0.1391%
AERS.L $86.83 1.5497%
OTLKW $0.03 0%
SFCA.PA $1.98 0%
CXAP.L $15 167.00 0.935%
PGRE $4.34 -1.9231%
1118.HK $0.75 1.3514%
ESYS.L $53.50 2.8846%
0P0000KM1W.L $21 362.50 -0.0734%
CI3.PA $231.29 -0.8998%
RYE $64.53 -0.1856%
RNER $4.99 0%
0QJQ.L $35.50 -0.1406%
IBMK $25.91 0%
GRAB $3.15 -2.0249%
DKS $139.94 0.4378%
8092.HK $0.03 0%
MEG $35.06 -2.1763%
1776.HK $11.98 -0.3328%
RLJ $10.62 -0.887%
0H7S.L $381.02 0%
O32.SI $1.76 0%
AKTX $0.18 1.6111%
CPNG $16.10 -1.7999%
LPSB3.SA $1.91 -4.9751%
COLL $22.98 -0.6485%
CEFA $28.54 -0.0406%
VHYA.L $61.31 -0.1466%
BSX $52.98 -0.7773%
VIC.L $77.00 -0.3881%
ALAVY.PA $1.08 0%
IVV $411.02 -0.7078%
PFEL $16.36 -2.677%
0990.HK $1.01 -2.8846%
NDP $27.57 0.1766%
PEI $2.39 75.7353%
TDF $9.32 -1.6878%
IAI $86.64 -0.471%
JREA.L $21.04 0%
0381.HK $0.04 -76.5432%
FPXS.L $4.22 0.3626%
BURL $172.28 -0.4392%
PHUNW $0.21 -2.2831%
0K34.L $59.33 0.5551%
HMUD.L $39.77 0.4166%
RF-PC $17.75 0.3392%
DOW $52.09 -0.4776%
CEDO3.SA $6.35 0%
HO.PA $138.50 1.7634%
POS.L $2.88 -5.6721%
1053.HK $0.85 -6.5934%
EXLS $148.55 -0.8709%
KCR.L $7.50 0%
IEDY.L $13.79 -0.2532%
NCSM $18.00 -2.3332%
CRBU $4.15 -5.2511%
CCPA.L $130.50 0%
IVE $150.04 -0.7934%
KT $11.81 1.0702%
M1GU.SI $0.44 0%
1555.HK $0.04 0%
3877.HK $1.39 0.7246%
LNFA $10.95 0%
MAA-PI $55.60 -0.1795%
AFGC $21.53 1.7005%
A17U.SI $2.86 -0.6945%
PAHC $13.98 -0.9568%
ARBE $2.09 -2.7907%
QUIZ.L $10.20 -5.9908%
JPBM.L $64.44 0.786%
ALIKO.PA $1.67 0.6024%
STM.L $24.50 0%
GEA.PA $88.00 -1.1236%
WWAC $10.30 0.0972%
AGL.L $20.75 -1.1905%
XBIOW $0.81 -32.9256%
AVGOP $1 406.70 0%
MILN $29.52 -1.056%
MMIN $24.35 -0.0407%
SUR.L $123.76 -0.3928%
ARIZR $0.11 10%
1588.HK $5.42 3.2381%
0LIY.L $336.15 1.4165%
SR-PA $24.84 -0.0604%
STAF $1.18 1.4483%
1141.HK $1.37 0%
DNMR $2.99 -2.7687%
AEIS $85.03 -0.6078%
JMF.L $904.00 0.4444%
ANAT $188.99 0%
TRTX $5.38 -0.5545%
CLVS $0.08 -24.1122%
1971.HK $1.92 0%
LUNA $7.43 4.6352%
GWX $31.04 -0.6564%
XIOR.BR $28.55 -0.349%
0QB4.L $17.55 -3.1891%
3393.HK $3.67 0.5479%
Eng
Логотип
Eng
Лого

ABIVAX Société Anonyme ABVX.PA

$18.26

+$2.32 (12.72%)
На 18:01, 12 мая 2023

Ранг: 3

Ранг - это оценка кредитоспособности корпорации.

Ключевые показатели

  • Marketcap

    685561320.00000000

  • week52high

    20.00

  • week52low

    5.60

  • Revenue

    37000

  • P/E TTM

    -6

  • Beta

    1.24923600

  • EPS

    -2.64000000

  • Last Dividend

    0.00000000

  • Next Earnings Date

    16 мар 2023 г. в 17:00

Описание компании

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

Свежие комментарии

Оставьте свой голос

Анонимное голосование

Будет ли рост российского рынка к концу года?

  • Да

    87%

  • Нет

    12%

Проголосовал 8 человек